 | • レポートコード：D0-MOR-AP0947 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、プレフィルド注射器の世界市場について調査・分析した資料で、プレフィルド注射器の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The market for prefilled syringes is believed to grow owing to factors such as increasing adoption of self-care devices, benefits associated with prefilled syringes, and high demand for improved safety in injectables.
The prefilled syringes make injections easy, accurate, and safe for both patients as well as doctors. Pre-filled syringes have emerged as one of the fastest-growing choices for unit dose medication, as the pharmaceutical industry seeks new and more convenient drug delivery methods.
In addition, pharmaceutical companies can get benefit by saving the cost of vials. The prefilled syringes work well with safety devices and auto-injection systems. Pharmaceutical companies are able to minimize drug waste and increase product life span, while patients are able to self-administer injectable drugs at their home instead of the hospital. Pre-filled syringes have also been utilized across a wide range of therapeutic sectors, such as vaccines, blood stimulants, and therapeutic proteins.
Eliminating dosing errors and ease of use are two of the greatest advantages of pre-filled syringes. Consequently, the differential advantages provided by prefilled syringes over traditional syringes are leading to its increased adoption and contributing to global market growth.
Key Market Trends
Glass Prefilled Syringes are Believed to Experience Highest Growth Over the Forecast Period
The pharmaceutical industry uses glass syringes manufactured from Type 1 borosilicate glass, which consists primarily of silicon dioxide, along with oxides of boron, aluminum, sodium, and potassium. Metal ions, specifically sodium dioxide, are included in the mixture to alter the physical properties of the glass.
Glass syringes are manufactured from tubing glass. The glass tubing is created by heating the glass mixture to approximately 1500°C and continuously pulling the molten glass along a hollow spindle. Processing conditions, such as speed and airflow, are tightly controlled to prevent failures, such as airlines in the glass, from occurring. While glasses are generally unreactive, they are not necessarily inert. Alkali metals can leach out of glass, resulting in pH shifts in the solution. Some drug molecules are also labile for adsorption to the charged surface of the glass, resulting in decreased potency of the drug solution.
There have been reported instances when tungsten residues in the glass syringe Luer cone left behind during manufacturing have led to aggregation and particle formation in protein solutions. Apart from the above-mentioned challenges of drug interaction, glass prefilled syringes are also prone to breakage.
The market for glass prefilled syringes will grow regardless, albeit very sluggishly in the forecast period, primarily due to increased adoption of prefilled syringes in the developing regions, where glass syringes provide reusability and lower cost.
North America Dominates the Market
On January 22, 2013, the US FDA published the long-anticipated Final Rule: “Current Good Manufacturing Practice Requirements for Combination Products”, with the purpose of clarifying regulatory requirements for quality systems used to design, develop, and manufacture combination products, and to help ensure consistent and appropriate application and enforcement of these requirements.
Prefilled drug delivery systems, including prefilled syringes, are combination products subject to the Final Rule. From a manufactures perspective, the Final Rule, as provided by the US FDA, tightens the regulations for syringe manufacturers and has made the manufacturing operation more stringent than before. This has acted as a deterrent to global players based in the United States and prevents them from expanding their regional operations, in other regions.
Overall, there is a large concentration of vendors supplying both end products and original components in the prefilled syringe market. The use of prefilled syringes in the United States is consequently ensured by the presence of appropriate vendors. Lifestyle associated illnesses and growing demand for easy-to-administer injectables in patients of chronic disease are helping the US prefilled syringe market flourish.
Competitive Landscape
The market for prefilled syringes is moderately competitive and there is high price competition in the market. The market is comprised of the global as well as local players. Most of the developing countries are having local players that provide prefilled syringes at a lower price. However, the market is majorly dominated by global companies. Few companies are expected to penetrate the market in the near future and they are beloved to grab a substantial share of the prefilled syringes market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Adoption of Self-care Devices
4.2.2 Benefits Associated with Prefilled Syringes
4.3 Market Restraints
4.3.1 Product Recalls
4.3.2 Availability of Alternate Drug Delivery Methods
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Material
5.1.1 Glass Prefilled Syringe
5.1.2 Plastic Prefilled Syringe
5.2 By Application
5.2.1 Diabetes
5.2.2 Anaphylaxis
5.2.3 Rheumatoid Arthritis
5.2.4 Oncology
5.2.5 Other Applications
5.3 By Type
5.3.1 With Needle
5.3.2 Without Needle
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Becton, Dickinson and Company
6.1.2 B. Braun Melsungen AG
6.1.3 Johnson & Johnson
6.1.4 Baxter International Inc
6.1.5 Terumo Corporation
6.1.6 Pfizer Inc.
6.1.7 Cardinal Health, Inc.
6.1.8 Teva Pharmaceuticals Industries Ltd
6.1.9 Fresenius SE & Co. KGaA
6.1.10 Mylan NV
6.1.11 Sanofi SA
7 MARKET OPPORTUNITIES AND FUTURE TRENDS